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Alarming data about increasing resistance to conventional antibiotics are reported,
while at the same time the development of new antibiotics is stagnating. Skin and
soft tissue infections (SSTIs) are mainly caused by the so called ESKAPE pathogens
(Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species) which belong to the
most recalcitrant bacteria and are resistant to almost all common antibiotics. S. aureus
and P. aeruginosa are the most frequent pathogens isolated from chronic wounds
and increasing resistance to topical antibiotics has become a major issue. Therefore,
new treatment options are urgently needed. In recent years, research focused on
the development of synthetic antimicrobial peptides (AMPs) with lower toxicity and
improved activity compared to their endogenous counterparts. AMPs appear to be
promising therapeutic options for the treatment of SSTIs and wounds as they show
a broad spectrum of antimicrobial activity, low resistance rates and display pivotal
immunomodulatory as well as wound healing promoting activities such as induction of
cell migration and proliferation and angiogenesis. In this review, we evaluate the potential
of AMPs for the treatment of bacterial SSTIs and wounds and provide an overview of
the mechanisms of actions of AMPs that contribute to combat skin infections and to
improve wound healing. Bacteria growing in biofilms are more resistant to conventional
antibiotics than their planktonic counterparts due to limited biofilm penetration and
distinct metabolic and physiological functions, and often result in chronification of
infections and wounds. Thus, we further discuss the feasibility of AMPs as anti-biofilm
agents. Finally, we highlight perspectives for future therapies and which issues remain to
bring AMPs successfully to the market.
Keywords: antimicrobial peptides, topical therapy, skin and soft tissue infections, wounds, wound healing,
bacterial resistance, biofilms, bacterial toxins
INTRODUCTION
Antimicrobial peptides (AMPs) are increasingly coming into the focus as new treatment strategies
for bacterial infections. But why new options have to be considered? The golden era of antibiotic
discovery that started almost one century ago when Fleming discovered penicillin in 1928 and that
can be accounted as one of the greatest achievements of modern medicine seems to be over. While
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up to the 1980s it was popular opinion that infections have
been conquered (Spellberg et al., 2004, 2008), today alarming
data about increasing resistance to conventional antibiotics are
reported occurring due to excessive use and misuse in medicine,
food industry, and agriculture. The current resistance situation
raises concerns about a post-antibiotic era with no antimicrobial
treatment options. At the same time, the development of new
anti-infective drugs is stagnating with only three new classes
of antibiotics during the last decades—all of them exclusively
directed against Gram-positive pathogens (Marr et al., 2006).
Estimates claim that by 2050 worldwide 10 million people a year
will die from infections caused by drug-resistant bacteria (Cordes
et al., 2014) and the World Health Organization classifies the
appearance of antibiotic resistance as one of the biggest threats
to human health.1
The so called ESKAPE pathogens (Enterococcus faecium,
Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter
baumannii, Pseudomonas aeruginosa, and Enterobacter species),
representing themost recalcitrant bacteria, are resistant to almost
all common antibiotics and are the leading causes of hospital-
acquired infections (Santajit and Indrawattana, 2016). As skin
and soft tissue infections (SSTIs) are mainly caused by S.
aureus, with MRSA (methicillin-resistant S. aureus) accounting
for 50% of all SSTIs, but also Gram-negative pathogens such as
P. aeruginosa and vancomycin-resistant Enterococcus (VRE) are
increasingly isolated, especially from chronic wounds, the current
resistance situation constitutes a major issue for the treatment of
these infections (Guillamet and Kollef, 2016). Moreover, SSTIs
rank among the most common bacterial infections in humans
(Sunderkotter and Becker, 2015) and increasing resistance is
reported against topical antibiotics such as fusidic acid or
mupirocin (Mendoza and Tyring, 2010; McNeil et al., 2011;
Guillamet and Kollef, 2016). Thus, new treatment options for
bacterial SSTIs are urgently needed. Although SSTIs can be
provoked by other microbes such as viruses, fungi and parasites,
Abbreviations: α-SMA, alpha-smooth muscle actin; AD, atopic dermatitis; AMP,
antimicrobial peptide; ATP, adenosine-triphosphate; COX, cyclooxygenase; DC,
dendritic cell; EGFR, epidermal growth factor receptor; ERK, extracellular signal-
regulated kinase; ESKAPE, Enterococcus faecium, Staphylococcus aureus, Klebsiella
pneumoniae,Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter
species; FPRL, formyl peptide receptor-like; GAS, group A streptococcus;
IFN, interferon; IL, interleukin; ILC, innate lymphoid cell; hBD, human β-
defensin; HDP, host defense peptide; HNP, human neutrophil peptide; i.m.,
intramuscular; JNK, c-Jun N-terminal kinase; KLK, kallikrein-related peptidase;
LP, lipoproteins/-peptides; LPS, lipopolysaccharide; MAP, mitogen-activated
protein; MCP, monocyte chemoattractant protein; mDC, myeloid dendritic cell;
MRSA, methicillin-resistant Staphylococcus aureus; MSSA, methicillin-sensitive
Staphylococcus aureus; mTOR, mechanistic target of rapamycin; NF-κB, nuclear
factor-kappa B; NOD2, nucleotide-binding oligomerization domain 2; P2X7R,
P2X7 receptor; PAMP, pathogen-associated molecular pattern; PBS, phosphate-
buffered saline; pDC, plasmacytoid dendritic cell; PI3K, phosphoinositide 3-
kinase; PLGA, poly (lactic-co-glycolic acid); PSM, phenol-soluble modulin; RNS,
reactive nitrogen species; ROS, reactive oxygen species; SSTI, skin and soft
tissue infection; STAT, signal transducer and activator of transcription; TGF-
β, transforming growth factor-beta; Th, helper T cell; TNF, tumor necrosis
factor; TLR, Toll-like receptor; VD3, vitamin D3; VRE, vancomycin-resistant
Enterococcus; VRSA, vancomycin-resistant Staphylococcus aureus.
1WHO: Antimicrobial resistance: Global report on surveillance 2014. http://www.
who.int/drugresistance/documents/surveillancereport/en/
this review focuses on bacterial skin infections since bacteria play
a major role for skin infections in humans.
AMPs, which are already known for several decades and are
part of the innate immunity from practically all living organisms,
ranging from bacteria, insects and plants to vertebrates, are
supposed to be promising candidates for the treatment of skin
infections and wounds. Their discovery started in 1939 with
the extraction of gramcidin from Bacillus brevis followed by the
isolation of cecropins and magainins in the 1980s (Kang et al.,
2017). During the last years substantial progress has been made
on the development and evaluation of AMPs for the treatment
of skin infections as well as acute and chronic wounds. The
purpose of this review is to discuss the suitability of AMPs
as potential therapeutics to treat bacterial skin infections and
wounds. Therefore, we will introduce the different opportunities
given by the application of AMPs for topical infections and
wounds, highlight their advantages and limitations and try
to contribute to answering the question if AMPs are indeed
promising candidates for the treatment of bacterial SSTIs and
wounds and which issues remain to introduce them successfully
to the market.
ANTIMICROBIAL BARRIER FUNCTION OF
THE SKIN
The skin is our outermost barrier and thus exposed to a
considerable number of diverse pathogens. Consequently, it has
to provide a vast arsenal of defense mechanisms. Apart from the
physical barrier that is preventing the penetration of microbial
organisms and mainly provided by the stratum corneum, the
outermost layer of the skin, the epidermis harbors an imposing
number of immune sentinels that are activated by invading
pathogens or barrier disruption (Bangert et al., 2011; Ryu et al.,
2014). A generalized structure of human skin and different cell
types populating the skin is shown in Figure 1.
Keratinocytes, the predominant cell type of the epidermis,
which do not only maintain the physical barrier, but are
central sentinels of the skin, greatly contribute to the defense
against bacterial skin infections. They express various Toll-
like receptors (TLRs) and nucleotide-binding oligomerization
domain 2 (NOD2) proteins which are essential for recognizing
pathogen-associated molecular patterns (PAMPs). Recognition
of PAMPs results in the activation of innate immunity involving
secretion of various cytokines and chemokines but also AMPs
which enable immune cells to be recruited to the site of infection
(Nestle et al., 2009; Krishna and Miller, 2012a). While activation
of TLRs in the skin is required for activation of innate immunity
and subsequent adaptive responses and thus for resolution
of infections, excessive stimulation can lead to overwhelming
inflammatory responses that might cause inflammatory skin
diseases, autoimmune diseases, or even sepsis (Lai and Gallo,
2008). In addition to keratinocytes, TLRs are expressed in dermal
fibroblasts and Langerhans cells located in the epidermis, but also
in other resident and trafficking immune cells such as monocytes,
macrophages and dendritic cells, lymphocytes, and mast cells.
Skin-residing cells show distinct TLR expression patterns and
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FIGURE 1 | Structure of human skin and cell types in epidermis and dermis. Skin appendages are not depicted and the list of cell types is non-exhaustive. Dendritic
epidermal T cell (DETC), dermal dendritic cell (dermal DC), innate lymphoid cell (ILC), plasmacytoid dendritic cell (pDC).
can therefore recognize distinct PAMPs to initiate different host
defense mechanisms (Miller, 2008).
PHYSIOLOGICAL ROLE OF AMPs IN THE
SKIN
A pivotal function of skin innate immunity is implemented by
AMPs. More than 20 AMPs have been identified in the skin
(Takahashi and Gallo, 2017). Since AMPs do not only possess
direct antimicrobial effects but are likewise able to enhance and
control immune responses as will be reviewed later, they are able
to strongly support the immune response triggered by bacteria.
All human body sites that are exposed to microbes such as
skin and mucosal epithelia are abundant with AMPs to prevent
colonization of host tissues by pathogens.
Endogenous AMPs are derived from immature pro-peptides
that have to be cleaved proteolytically to obtain biologically
active mature peptides (Hemshekhar et al., 2016). The best
characterized AMPs in humans—the cathelicidin LL-37 and
the defensins—are produced by various cell types, including
keratinocytes, macrophages, neutrophils, mast cells and dendritic
cells (Krishna and Miller, 2012b; Afshar and Gallo, 2013).
To generate LL-37, the parent cathelicidin molecule hCAP18
has to be processed via proteinase 3 in neutophils and via
kallikreins in keratinocytes (Takahashi and Gallo, 2017). The
most important source for AMPs in the skin are keratinocytes
that constitutively express AMPs such as human β-defensin 1
(hBD1), while others like hBD2-4 are induced when exposed
to injury or infection. The expression of hBD2 for example can
be induced by bacterial components targeting TLR2 or TLR4.
LL-37 is constitutively expressed in neutrophils, but can also
be induced by vitamin D3 (VD3) or lipopolysaccharide (LPS)
in keratinocytes (Bernard and Gallo, 2011). The subsequently
recruited neutrophils andmast cells are likewise producing AMPs
resulting in a strong AMP increase which is leading to the
stimulation of angiogenesis and proliferation of keratinocytes
to repair the injured tissue (Lee et al., 2005; Afshar and Gallo,
2013). α-defensins (human neutrophil peptides—HNPs) are
highly expressed in neutrophils which account for almost 50%
of neutrophil granules (Ryu et al., 2014). Furthermore, the
cationic peptide RNase7 is produced in keratinocytes, while the
anionic peptide dermcidin is produced by human eccrine sweat
glands (Bangert et al., 2011). The AMP psoriasin was found to
protect the skin against E. coli infection (Glaser et al., 2005).
AMPs are also produced by commensal bacteria such as phenol-
soluble modulin (PSM-)γ which is expressed in Staphylococcus
epidermidis (Takahashi and Gallo, 2017) and displays direct
antimicrobial activity against S. aureus and indirect by activating
TLR2 on keratinocytes, thereby enhancing the production of
endogenous AMPs (Ryu et al., 2014). Mast cells were only
recently recognized to play a role for immune defense against
skin infections by producing cathelicidin peptides which recruit
neutrophils and show a direct antimicrobial effect and thus
protect from GAS (group A streptococcus) skin infection and
help to prevent the extension of localized Gram-positive skin
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infections (Di Nardo et al., 2008). On the other side, the
expression of cathelicidins in mast cells contributes to skin
inflammation in rosacea (Muto et al., 2014) demonstrating the
dual role of AMPs.
AMPs AND SKIN DISEASES
The function of AMPs in the skin is outlined by their role in skin
diseases such as psoriasis or atopic dermatitis (Figure 2). While
AMPs are downregulated in skin lesions of atopic dermatitis
patients, thus predisposing patients to S. aureus skin infections,
they are upregulated in psoriasis and rosacea where they worsen
the inflammation that correlates with disease severity.
Mice with disrupted Cnlp (gene coding for CRAMP) show an
increased susceptibility to skin infections (Ramos et al., 2011)
and the deficiency of LL-37 in chronic ulcers—probably due
to bacterial proteases—may influence their healing process. In
contrast, hBD-2, 3, and 4 are overexpressed in diabetic foot
ulcer, but not sufficient to control wound healing and infections
(Rivas-Santiago et al., 2012).
In psoriasis, production of LL-37 and hBD-2 is increased,
whereas LL-37 is able to form complexes with self-RNA resulting
in the activation of TLR7 in plasmacytoid dendritic cells
(pDCs) and TLR8 in myeloid DCs and to enable pDCs to
recognize self-DNA through TLR9 and therefore contributes
to psoriasis pathogenesis by IFN-γ-induced activation of
myeloid dendritic cells (mDCs) and keratinocytes and
Th1/Th17 differentiation (Bangert et al., 2011; Takahashi
and Gallo, 2017). Likewise, hBD2, hBD3, and lysozyme were
shown to induce pDC activation in psoriasis (Lande et al.,
2015).
Rosacea is accompanied by up-regulation of TLR2 which in
turn triggers cathelicidin production leading to abnormally high
levels in the epidermis and unusual cathelicidin cleaving products
(Dutta and Das, 2015). A role of LL-37 in the pathogenesis of
rosacea could be demonstrated by the application of ivermectin
in keratinocytes and 3D skin models which displayed an anti-
inflammatory effect by suppressing expression of LL-37 and
the protease kallikrein-related peptidase (KLK)5 (Thibaut de
Menonville et al., 2017).
Cathelicidins, hBD-2 and 3 and dermcidin are down-
regulated, while RNase7 and psoriasin are up-regulated in atopic
dermatitis (AD) lesions (Takahashi and Gallo, 2017). Down-
regulation of AMPs in atopic dermatitis might be supported
by the presence of Th2-derived cytokines IL-4, IL-10, and IL-
13 which suppress the induction of AMPs. However, AMPs
can also play a pathogenic role in AD by stimulating the
production of Th2-derived cytokines which are involved in AD
pathogenesis (Niyonsaba et al., 2017). On the other side, it could
be demonstrated that hBD-3 improves the skin barrier function
which is impaired in AD (Kiatsurayanon et al., 2014).
In acne vulgaris, various AMPs are upregulated in
keratinocytes and sebocytes induced by Cutibacterium (formerly
Propionibacterium) acnes which might worsen the inflammatory
response due to pro-inflammatory effects displayed by the
AMPs or might be beneficial due to anti-inflammatory and
antimicrobial effects (Korting et al., 2012; Niyonsaba et al., 2017).
FIGURE 2 | Regulation of endogenous AMPs in different skin diseases. In psoriasis, LL-37 is forming complexes with self-DNA or -RNA, thus leading to the activation
of plasmacytoid dendritic cells (pDCs) and myeloid dendritic cells (mDCs) which trigger Th1 and Th17 responses by secretion of IL-12 and IL-23. Rosacea is
characterized by increased TLR2 expression which triggers LL-37 production and increases protease activity leading to unusual LL-37 cleavage products. In atopic
dermatitis, Th2-derived cytokines suppress the induction of AMPs. In acne vulgaris, C. acnes (formerly P. acnes) induces up-regulation of AMPs in keratinocytes and
sebocytes.
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STRUCTURE AND MODE OF ACTION OF
AMPs
Antimicrobial peptides are evolutionarily conserved components
of the innate immune system from almost all species of life
ranging from plants and insects to complex animals. Bacteriocins
with lantibiotics as the most popular group are produced by
bacteria and used as food preservatives (Ben Lagha et al., 2017).
Insect AMPs are one of the largest groups of known antibiotics
and can be detected in insect haemolymph as early as 2–4 h
after a septic injury (Hoffmann et al., 1993; Meister et al., 1997).
Defensins are an important part of the innate immunity in
plants and show strong antifungal activity (Parisi et al., 2018).
Additionally, several AMPs have been isolated from frog skin
and show potential activity against skin infections (Ladram and
Nicolas, 2016; Liu et al., 2017). More than 2,800 natural peptides2
are currently known that, despite being of variable length,
sequence, and structure, share pivotal characteristics that are
decisive for their mode of action. The structure of representative
natural and synthetic AMPs is shown in Table 1. For details on
structure and mechanism of action of AMPs we refer to other
recent reviews (Jenssen et al., 2006; Nguyen et al., 2011; Wang,
2014).
Most AMPs are small (12–50 amino acids) and have a positive
net charge (+2 to+9) and∼50% hydrophobic residues enabling
them to fold into an amphiphilic confirmation when they interact
with bacterial membranes. This structure is essential for their
mechanism of action as initial electrostatic interaction between
the cationic peptides and the anionic constituents of the bacterial
membrane is not sufficient for their antimicrobial action. Rather
TABLE 1 | Primary sequences of selected natural and synthetic antimicrobial
peptides with wound-healing activities.
















Amino acid sequences are given in one-letter code. Lowercase letters indicate D-amino
acid residues.
2The Antimicrobial Peptide Database (APD). http://aps.unmc.edu/AP/
insertion into the bacterial lipid membrane in a second step is
required resulting in transmembrane pore forming, formation
of ion channels, or membrane disruption (Kaconis et al., 2011;
Mangoni et al., 2015).
AMPs are more or less selective for bacterial membranes
since mammalian membranes are enriched with zwitterionic
rather than with negatively charged phospolipids and possess
cholesterol which protects the membrane from damaging effects
by reducing the activity of AMPs stabilizing the lipid bilayer or by
directly interacting and neutralizing them (Giuliani et al., 2007).
Two classes of AMPs mainly targeting bacterial membranes
are described: membrane disruptive and non-membrane
disruptive AMPs with intracellular targets which may
act independently or synergistically with membrane
permeabilization (Giuliani et al., 2007). For the pore formation
induced by membrane disruptive peptides different models
are suggested such as the barrel-stave (e.g., for alamethicin) or
toroidal-pore model (e.g., magainin II, melittin or LL-37), carpet
model (e.g., polymyxin B, dermaseptin, cecropins) (Falanga
et al., 2016) and aggregate model (e.g., indolicidin) (Giuliani
et al., 2007) where cell death occurs owing to metabolite leakage,
cell lysis, or dissipation of electrochemical ion gradients from
the bacterial cell membrane. The direct antimicrobial effect,
however, occurs not only due to membrane rupture, but also
extends to interference with enzymes, cell wall synthesis, nucleic-
acid synthesis, and protein synthesis when non-membrane
disruptive peptides translocate across the bacterial cellular or
the nuclear membranes to access intracellular targets (Brogden,
2005; Ageitos et al., 2017). For example, buforin II inhibits DNA
and RNA synthesis, while PR-39 decreases protein synthesis and
phyrrhocidin and apidaecin target the ATPase activity of DnaK
resulting in the accumulation of misfolded proteins and thus cell
death.
Most AMPs show rapid and broad-spectrum antimicrobial
properties (Jenssen et al., 2006; Brogden and Brogden, 2011;
Mojsoska and Jenssen, 2015). However, several AMPs possess
multiple targets and can simultaneously target the membrane
and intracellular molecules such as NK-18, a truncated peptide
derived from the core region of NK-lysin, which is membrane-
active, but can also interact with plasmid and genomic DNA from
E. coli (Yan et al., 2013).
Comparable to the antibacterial activity of AMPs, antifungal
effects are mainly based on two distinct mode of actions.
Membrane traversing peptides can lead to pore formation
or have specific fungal targets such as β-glucan or chitin
synthesis, while non-membrane traversing peptides interact
with the cell membrane and cause cell lysis (Bondaryk
et al., 2017). Porcine myeloid antimicrobial peptide-36-derived
peptides showed antifungal activity against Candida albicans
via membrane disruption (Lyu et al., 2016) and a synthetic
multivalent antifungal peptide displayed higher antifungal
activities against Candida and Fusarium strains than azoles
or polyene antifungals by selectively damaging the fungal
membrane (Lakshminarayanan et al., 2014). Histatin 5 was
internalized by C. albicans and acted on mitochondrial
membranes, whereas its activity was dependent on the energy
status of the fungal cell (Ruissen et al., 2001). In contrast,
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antifungal activity of the cathelicidins LL-37 and CATH-2 did not
depend on the cellular energy-status, but they rapidly localized
to the cell membrane, whereas at sub-MFCs small amounts of
the peptides were internalized, suggesting additional intracellular
targets (Ordonez et al., 2014). Moreover, naturally produced
cathelicidins are present at fungal infection sites and might form
a barrier to C. albicans infection (Lopez-Garcia et al., 2005).
Some AMPs display strong antiviral activity by integration
into the viral envelope or host cell membrane (Lakshmaiah
Narayana and Chen, 2015). They can bind to heparan sulfate
moieties on the cell surface and thus prevent infection with
distinct enveloped viruses including herpes simplex virus (HSV)-
1 and -2 (Krepstakies et al., 2012), or disrupt the envelope and/or
capsid of adenovirus and HSV-1 (Gordon et al., 2009). LL-37 was
able to enhance the antiviral activity induced by double-stranded
RNA in keratinocytes and was potent against influenza virus A,
probably by disrupting the viral membrane, and LL-37 expression
in keratinocytes and B cells reduced the viral load of varicella
zoster virus (Takiguchi et al., 2014; Wang et al., 2014).
AMPs can also be active against parasites, whereas most
studies focus on their activity against Plasmodium and
Leishmania (Vizioli and Salzet, 2002). Oocyst development
in Plasmodium spp. was reduced by cecropin and magainin
(Gwadz et al., 1989) and insect defensins were highly toxic to
isolated sporozoites in vitro (Shahabuddin et al., 1998), while
dermaseptin killed Leishmania by altering the permeability of
the plasma membrane (Hernandez et al., 1992).
Beyond direct antimicrobial activity, AMPs also may inhibit
the strong inflammation induction caused by the bacterial
PAMPs (pathogenicity factors, also called toxins), essentially
lipopolysaccharides (LPS, endotoxins) for Gram-negative
and lipoproteins, -peptides (LP) for Gram-positive strains
(Brandenburg et al., 2016). The findings in various studies that
peptidoglycans and lipoteichoic acids are also relevant toxins,
could not be verified (Martinez de Tejada et al., 2015), because
the inflammation signals induced by LP were by at least two
orders of magnitude higher that those induced by the latter
compounds.
Besides the indicated antimicrobial and anti-toxin activity,
AMPs may also have immunomodulatory functions which
are often physiologically more relevant. AMPs may facilitate
clearance of pathogens by modulating cellular immune
responses, for example by reducing the levels of pro-
inflammatory cytokines, modulating the expression of
chemokines and reactive oxygen (ROS) and nitrogen (RNS)
species, stimulating angiogenesis, enhancing wound healing,
and activate and/or differentiate leukocytes and macrophages
(Hilchie et al., 2013). As example, it was reported, that the
particular peptide IDR-1, a 13-mer, was successful in protecting
mice against Gram-negative and Gram-positive bacteremia, and
at the same time, the innate immune system was stimulated
by the peptide by increasing the expression of cytokines and
chemokines (Scott et al., 2007). Here and in other investigations
of the immune-modulating activity of peptides, however, it
was not analyzed whether the compounds show any binding
affinity to the bacterial toxins which are responsible for the heavy
inflammation. Therefore, despite the described encouraging
animal experiments, the application of immunomodulating
compounds so far did not result in an improvement of the
situation of critically ill patients (Opal et al., 2014).
On the basis of their secondary structure AMPs can be
classified into four major categories: α-helical like the human
cathelicidin LL-37 (Zeth and Sancho-Vaello, 2017), β-sheet with
α-, β-, und θ-defensins as representatives, loop (stabilized by
a disulfide bridge, e.g., esculentin-1; Mangoni et al., 2015) and
extended peptides which are rich in particular amino acids such
as tryptophane in indolicidin.
STRUCTURAL REQUIREMENTS FOR THE
ANTIMICROBIAL ACTIVITY
A number of different structural requirements are essential to
obtain strong antimicrobial activity of AMPs. For synthetic
peptides derived from the human cationic peptide ubiquicidin
a correlation between the isoelectric point value and the
antimicrobial activity against MRSA in vitro and in vivo could
be demonstrated (Brouwer et al., 2006). Furthermore, the highest
antimicrobial activity toward MRSA was achieved with synthetic
fragments containing an α-helix, while peptides containing
a β-sheet only displayed poor activity, probably due to low
lipophilicity and linear charge density. The extent and ratio
of cationicity, hydrophobicity, α-helicity, and amphipathicity of
AMPs are decisive for the antimicrobial and cytolytic activity. For
the frog skin peptide kassinatuerin-1 and its L- and D-lysine-
substituted derivates increasing cationicity with maintaining
the amphipathic α-helical character enhanced the antimicrobial
potency against Gram-positive bacteria, but also hemolytic and
cytolytic activity. On the contrary, analogs with D-amino acids
retained activity against Gram-negative bacteria, while their
hemolytic and cytolytic activity was reduced. However, due to the
D-amino acid substitution the α-helicity and thus potency against
Gram-positive bacteria were decreased.
In general, an increase in positive charge facilitates the
interaction of AMPs with the bacterial cell wall, but increases
hemolytic activity (Conlon et al., 2005). Also reducing the
hydrophobicity of AMPs can reduce hemolytic activity (Giuliani
et al., 2007). Another group investigated the effect of D-amino
acids that were introduced into non-cell-selective α-helical AMPs
on cell selectivity and protease-stability, depending on the
number and distribution of D-amino acids introduced (Wang
et al., 2010). Increase of D-amino acids and dispersed distribution
rather than segregated distribution of the D-amino acids caused
increase in cell selectivity toward bacterial cells. Furthermore,
introduction of D-amino acids caused complete resistance to
tryptic digestion. Increasing hydrophobicity and α-helicity of
these peptides increased their hemolytic and anti-inflammatory
activity. The short synthetic peptides RRIKA and RR showed
potent antimicrobial activity against clinical and drug-resistant
S. aureus isolates with stronger effects when amphipathicity,
hydrophobicity, and net charge were increased (Mohamed et al.,
2014). Bacterial killing appeared due to pore formation and
disruption of the bacterial membrane leading to leakage of
cytoplasmic contents and cell lysis, but also DNA binding could
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be demonstrated for the peptides. Importantly, RRIKA was still
active in the presence of 10% fetal bovine serum and both
peptides retained their antibacterial activity in the presence of
increasing salt concentrations.
COMMON BACTERIAL SKIN INFECTIONS
Skin and soft tissue infections (SSTIs) rank among the most
common bacterial infections in humans and bacteria accountable
for SSTIs show increasing resistance against commonly used
antibiotics (Eckmann and Dryden, 2010; Amara et al., 2013).
Bacterial SSTIs can range from superficial, often self-limiting
mild infections without requirement for antibiotic treatment
to complicated infections that result in the development of
sepsis with lethal outcome. Different classifications for SSTI are
proposed. A classification frequently used in clinical trials which
is provided by the FDA differentiates between uncomplicated
and complicated SSTI, while for the latter major surgical
intervention might be necessary or deep soft tissue is involved
with signs of systemic sepsis (Eckmann and Dryden, 2010).
Systemic infection and involvement of deeper tissues is largely
mediated by toxins that are produced by bacteria and by the
host response to infection. Especially for complicated SSTIs,
an epidemiological shift toward drug-resistant bacteria can be
observed. S. aureus as the major cause of nosocomial wound
infections is secreting toxins, virulence factors and exoproteins
resulting in delayed wound healing, prolonged inflammation
and chronic infection. Additionally, skin infections caused by
S. aureus or P. aeruginosa frequently lead to invasive infections
that might result in sepsis (Thangamani et al., 2015; Guillamet
and Kollef, 2016). While S. aureus is the most common
cause of SSTIs worldwide, followed by β-hemolytic streptococci,
E. coli, and P. aeruginosa, chronic or postoperative wounds
are predominantly caused by Gram-negative bacteria such as
P. aeruginosa, Enterococcus, and Acinetobacter species (Cardona
and Wilson, 2015; Esposito et al., 2016; Guillamet and Kollef,
2016). Furthermore, community-acquired MRSA is increasing
which causes 60–80% of staphylococcal skin infections in the US
(Stein and Wells, 2010). Notably, it could be observed that the
inflammatory response after a bacterial infection contributes to
the clinical severity of S. aureus skin infections rather than the
bacterial burden (Mohamed et al., 2014).
CURRENT CHALLENGES OF
CONVENTIONAL ANTI-INFECTIVES AND
SIGNIFICANCE OF AMPs FOR THE
TREATMENT OF SSTIs
After pneumonia and abdominal infections, SSTIs are the
third most cause of severe sepsis or septic shock (Eckmann
and Dryden, 2010). Conventional antibiotics, especially those
targeting the bacterial cell wall, might display themajor drawback
of triggering the release of bacterial pathogenicity factors and
therefore may even worsen the outcome of an infection by
triggering sepsis or septic shock, as demonstrated for the
antibiotic ciprofloxacin (Brandenburg et al., 2011; Heinbockel
et al., 2013; Brandenburg and Schürholz, 2015). Chronic
wounds such as diabetic wounds are often accompanied by
excessive release of pro-inflammatory cytokines, thus remaining
in the inflammatory phase of wound healing and can also be
accompanied with insufficient angiogenesis (Liu et al., 2014a).
Here, the mode of action of AMPs that neutralize bacterial
pathogenicity factors or control and balance the host immune
response rather than acting directly on bacteria, might be
favorable to improve the outcome of infections; on the one
side by enhancing levels of immune cells and chemokines that
are clearing infections and on the other side by decreasing
pathogenicity factor-induced secretion of pro-inflammmatory
cytokines (Mansour et al., 2015; Brandenburg et al., 2016).
Antimicrobial peptides display major advantages compared
to conventional antibiotics. Besides their broad-spectrum
activity against various strains of Gram-positive and Gram-
negative bacteria, including drug resistant strains, they show
a different mode of action which is not involving specific
protein binding sites or can involve multiple bacterial cellular
targets making resistance development rather unlikely (Marr
et al., 2006; Wimley and Hristova, 2011; Seo et al., 2012).
Importantly, they successfully retained their antimicrobial
activity for millions of years. Furthermore, only their direct
antimicrobial effect is affected by bacterial resistance, whereas
their immunomodulatory properties stay unaffected (Stein and
Wells, 2010). Particularly SSTIs are an attractive target for
the application of AMPs since topical treatment circumvents
potential systemic adverse effects and can achieve high drug
concentrations at the target site.
On the other side, AMPs possess some limitations that
hamper their clinical and commercial development such as high
production costs, potential toxicity, susceptibility to proteases
(also in the wound fluid), and unknown pharmacokinetics
(Dutta and Das, 2015). Nevertheless, various approaches are
already offered including insertion of non-natural or D-amino
acids, introduction of peptide-mimetics, peptide cyclisation,
acetylation, or amidation at the N-terminus to avoid peptide
degradation (Giuliani et al., 2007) or the design of short peptides
to reduce production costs. Also the use of drug delivery systems
like liposome encapsulation might help to improve their stability
and reduce their toxicity (Seo et al., 2012). Therefore, several
synthetic AMPs were produced that show promising effects in
vivo after topical application on infected skin with lower toxicity
than AMPs used in clinical practice such as colistin and with the
advantage to not select for resistant mutants in bacterial cultures
(Brunetti et al., 2016).
RESISTANCE TO AMPs
Bacterial resistance against AMPs has already been reported
(Ouhara et al., 2008; Andersson et al., 2016; Omardien et al.,
2016) holding the risk that bacteria that evolve resistance against
externally applied AMPs might develop cross-resistance to host
AMPs or antibiotic therapy (Dobson et al., 2014; Kubicek-
Sutherland et al., 2017), such as S. aureus which developed
resistance to HNP-1 after treatment with pexiganan (Conlon,
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2015). However, synthetic peptides which do not appear in
nature, could overcome the obstacle of resistance to natural
host defense peptides (HDPs) (Nijnik and Hancock, 2009).
Figure 3 summarizes the main bacterial resistance mechanisms
against AMPs. Resistance of bacteria to AMPs might develop
due to changing of their net surface charge, whereas mainly
modification of LPS in Gram-negative and lipoteichoic acid in
Gram-positive bacteria by increasing positive charges reduces
the attraction of AMPs (Joo et al., 2016). Further, release
of proteases and therefore proteolytic degradation of the
peptides is a potential resistance mechanism. Commensal
bacteria on epithelial surfaces produce various proteases such
as metalloproteases or serine endopeptidases. Inactivation of
AMPs by bacterial proteases strongly depends on the peptide
structure, given a higher susceptibility to degradation of linear
peptides compared to cyclic peptides containing disulfide
bonds. Modifications of the bacterial phospholipid composition
and thus alteration of the cytoplasmic membrane structure
such as amino acylation of phosphatidylglycerol head groups,
which masks anionic phosphates with cationic primary amines,
decreases AMP attraction and membrane insertion. Also
eﬄux pumps belonging to the RND (resistance-nodulation-
cell division) family transporters in Gram-negative bacteria
contribute to AMP resistance. Sequestering of AMPs, e.g.,
of HNP-1 and -2 by S. aureus staphylokinase, or down-
regulation of host AMP production by interference with or
suppression of AMP production further protects bacteria from
AMPs (Andersson et al., 2016; Cole and Nizet, 2016; Joo et al.,
2016). Resistance to AMPs can further reduce susceptibility
to antibiotics (Kubicek-Sutherland et al., 2017). Resistance
mechanisms that contribute to virulence in vivo are modification
of cell surface structures and eﬄux transporters whereas only
few studies demonstrated a contribution of proteases to AMP
resistance in vivo (Bauer and Shafer, 2015).
AMPs FOR THE TREATMENT OF SSTIs
Wound Healing
The epidermis provides a protective barrier against microbial
pathogens. However, this barrier can be disrupted by wounding,
thus allowing microbial pathogens to invade the underlying
FIGURE 3 | Possible bacterial resistance mechanisms against AMPs.
tissue. After wounding, a complex wound healing process
is initiated which comprises three phases. The inflammatory
phase is dominated by blood clot formation and invasion of
immune cells such as neutrophils and macrophages, the second
phase comprises tissue formation with angiogenesis and re-
epithelialization and the third phase includes remodeling with
collagen synthesis (Werner and Grose, 2003). Adequate wound
closure is a prerequisite for maintaining skin homeostasis since
failures during wound recovery can cause the formation of
chronic wounds which often remain in the inflammatory stage
and are challenging to heal (Portou et al., 2015). Chronic
wounds like diabetic, pressure and venous leg ulcers are mainly
polymicrobial and most frequently caused by S. aureus and P.
aeruginosa. While S. aureus is usually located in the top layer of
the skin, P. aeruginosa is detected in the deepest region of the
wound bed (Serra et al., 2015). Infection of wounds can lead to
bacteremia or sepsis and is accompanied by high mortality and
morbidity (Hirsch et al., 2009).
Various studies reveal the importance of natural AMPs in
wound healing which are upregulated in all stages of wound
recovery (Niyonsaba et al., 2017). LL-37 is upregulated in
skin wounds and LL-37 antibodies suppress re-epithelialization,
while in chronic ulcers LL-37 expression is low (Heilborn
et al., 2003). On the contrary, adenovirus-mediated LL-37 gene
transfer to excisional wounds in obese mice improved re-
epithelialization and granulation tissue formation (Carretero
et al., 2008). Most wounds are contaminated by bacteria and
colonization of wounds can result in delayed or impaired wound
healing. For treatment of infected wounds AMPs should display
low cytotoxicity and broad-spectrum antimicrobial activity, they
should promote wound closure and be stable in the host
environment with high salt concentrations and in the presence
of proteases secreted by the host, e.g., in the wound fluid, or
by invading microbes in the wound site (Kim et al., 2014).
In the wound fluid more than 100 endogenous proteases are
identified such as metalloproteases and neutrophil elastase, but
also proteases from bacteria that contaminate wounds such as S.
aureusV8 proteinase. The synthetic peptide SHAP1 showed high
stability in the presence of proteases and high salt concentrations
and therefore was able to promote wound healing in vivo at
the same low concentrations used in vitro (Kim et al., 2014).
Degradation by proteases might be less relevant for AMPs
showing rapid killing of bacteria. The designer peptide novispirin
G10 killed bacteria within 4 h after intradermal injection into
a P. aeruginosa-infected, partial-thickness burn wound before
it was inactivated by proteases (Steinstraesser et al., 2002).
Furthermore, rapid bactericidal activity of AMPs shows the
advantages over conventional antibiotics to reduce the treatment
duration and the potential for resistance development (Mohamed
et al., 2016). On the other side, for peptides such as LL-
37 which are unstable in the presence of proteases, much
higher concentrations will be required to obtain a therapeutic
effect in vivo. A recent study showed that omiganan probably
failed clinical trials due to the degradation by skin proteases
which could be overcome by using the all-D enantiomer (Ng
et al., 2017). AMPs display various mechanisms that support
wound healing of infected as well as non-infected wounds that
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will be summarized below. Table 2 provides an overview of
different endogenous and synthetic AMPs and their role in
different stages of wound healing. For some AMPs wound closure
in mice was only accelerated in infected, but not in aseptic
wounds (Huang et al., 2014), probably by facilitating wound
recovery due to combating infection, whereas synthetic and
recombinant LL-37 supported wound regeneration in a sterile
wound model in dexamethasone-treated mice by increasing
vascularization and re-epithelialization (Ramos et al., 2011).
Hence, different mechanisms of AMPs affect distinct steps of the
wound healing process. While AMPs with immunomodulatory
and antimicrobial properties might be used to treat infected
wounds, an influence on migration and proliferation of skin cells
is essential to support healing of non-infected wounds.
Treatment of Non-infected Wounds
AMPs provide different influences on the inflammatory phase by
enhancing or decreasing the immune response. While tylotoin,
a peptide from salamander skin with no antimicrobial activity,
increased recruitment of macrophages to the wound site and
promoted transforming growth factor (TGF)-β release from
macrophages (Mu et al., 2014), the peptide CW49 from frog
skin reduced macrophage recruitment and secretion of pro-
inflammatory cytokines andmight thus be used for the treatment
of non-healing wounds associated with excessive inflammation
(Liu et al., 2014a). Also the designer peptide tiger17 recruited
macrophages to the wound site during the inflammatory phase
and promoted TGF-β and interleukin (IL)-6 release from
macrophages via activation of c-JunN-terminal kinase (JNK) and
extracellular signal-regulated kinase (ERK) mitogen activated
protein (MAP) kinase pathways (Tang et al., 2014). AH90, a
peptide from frog skin, induced wound healing by promoting
TGF-β release frommacrophages via activation of nuclear factor-
κB (NF-κB) and JNK signaling pathways (Liu et al., 2014b).
A number of peptides act via epidermal growth factor receptor
(EGFR) transactivation and thus promote cell migration,
a pivotal step during re-epithelialization, which is essential
for adequate wound closure. This mechanism has been
demonstrated for naturally occurring AMPs such as LL-37
(Tokumaru et al., 2005), melittin (Sommer et al., 2012), and
SPINK9 (Sperrhacke et al., 2014), the frog-skin derived peptide
esculentin-1a(1-21)NH2 (Di Grazia et al., 2015b), but also for
the synthetic peptides Pep19-2.5 and Pep19-4LF (Pfalzgraff
et al., 2016), DRGN-1 (Chung et al., 2017), and SHAP1
(Kim et al., 2014). EGFR transactivation is mediated via
metalloprotease-dependent cleavage of membrane-bound EGFR
ligands resulting in downstream activation of ERK1/2 or signal
transducer and activator of transcription 3 pathway which
ultimately promotes keratinocyte migration and/or proliferation
(Figure 4). This effect seems to be stereospecific as an all-D-
enantiomer of esculentin-1a(1-21)NH2 was not able to stimulate
keratinocyte migration (Di Grazia et al., 2015b). Recent studies
indicate that EGFR transactivation occurs via peptide-mediated
activation of purinergic receptors, particularly the P2X7 receptor
(P2X7R) seems to play a critical role (Figure 4; Sommer
et al., 2012; Sperrhacke et al., 2014; Pfalzgraff et al., 2016;
Comune et al., 2017). However, it is unclear whether the
peptides indirectly activate the P2X7R or act as allosteric
modulators similar to polymyxin B (Ferrari et al., 2004).
For other AMPs the involvement of distinct receptors and
pathways in cell migration and proliferation was demonstrated,
such as the phosphoinositide 3-kinase (PI3K)/Akt/mechanistic
target of rapamycin (mTOR) pathway (Tomioka et al., 2014)
or G-protein coupled receptors, phospholipase C, EGFR,
PI3K, ERK, and p38 MAPK (Hoq et al., 2011). Intriguingly,
while some peptides solely influence cell migration but not
proliferation (Carretero et al., 2008; Kim et al., 2014; Pfalzgraff
et al., 2016), others are stimulating both (Niyonsaba et al.,
2007; Sommer et al., 2012) despite their collective mode of
action involving EGFR transactivation. Therefore, the EGFR
downstream signaling pathways linked to peptide-induced cell
migration and proliferation need to be explored further.
In vivo, AMPs strongly accelerate wound healing via
induction of re-epithelialization and granulation tissue formation
(Heilborn et al., 2003; Mu et al., 2014; Tang et al., 2014).
The formation of new blood vessels which also belongs to the
second wound healing stage can be supported by AMPs as
well. Tylotoin promoted angiogenesis by inducing endothelial
cell tube formation (Mu et al., 2014), while CW49 up-regulated
angiogenic proteins (Liu et al., 2014a), WRL3 increased vascular
endothelial growth factor production (Ma et al., 2017), and
LL-37 mediated angiogenesis via formyl peptide receptor-like 1
(Koczulla et al., 2003).
Also the third wound healing stage can be supported by
AMPs. SR-0379 promoted contraction capacity of human dermal
fibroblast cells and accelerated in vivo wound healing by
increasing collagen production (Tomioka et al., 2014) and Epi-
1 enhanced the formation of collagen around the wound region
(Huang et al., 2017). Other peptides can induce fibroblast-
to-myofibroblast differentiation (Liu et al., 2014b; Mu et al.,
2014; Tang et al., 2014) which synthesize extracellular matrix
components such as collagen (Gabbiani, 2003). Further, α-
smooth muscle actin expression can be increased in fibroblasts,
therefore inducing wound contraction (Park et al., 2017).
Treatment of SSTIs and Infected Wounds
Since skin barrier disruption is accompanied with high risk
of infections and bacteria like S. aureus and P. aeruginosa
prolong the inflammatory phase of wound healing, AMPs
might facilitate wound recovery by combating the concomitant
infection. The AMP proline-novispirin G10 (P-novispirin G10)
strongly reduced bacterial counts within 3 days in a porcine
infected wound chamber model using S. aureus. The rapid
activity of the peptide led to killing of bacteria before peptide
degradation and inactivation (Jacobsen et al., 2007). PXL150
showed rapid and strong antimicrobial effects by changing
the membrane potential of S. aureus in an in vivo model
of full-thickness wounds in rats infected with MRSA and
in an ex vivo model of pig skin infected with S. aureus
(Myhrman et al., 2013). Formulated in hydroxypropyl cellulose
gel PXL150 rapidly reduced bacterial counts in an in vivo
mouse model of P. aeruginosa infected burn wounds (Björn
et al., 2015). In a mouse wound infection model, K1K8
was as effective as mupirocin ointment in reducing MRSA
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TABLE 2 | Role of selected natural and synthetic antimicrobial peptides during wound-healing phases.
Peptides Inflammatory phase (Phase 1) Tissue formation phase with
angiogenesis and
re-epithelialization (Phase 2)
Remodeling phase with collagen
synthesis (Phase 3)
References




formation, up-regulation of integrins
TGF-β ↑ → α-SMA ↑ →
fibroblast-to-myofibroblast transition
Liu et al., 2014b
Catestatin Keratinocyte migration and
proliferation via GPCRs, PLC, EGFR,
Akt/PI3K, MAPK
Hoq et al., 2011
CW49 Macrophage recruitment and
pro-inflammatory cytokines ↓ in
diabetic wounds
HUVEC tube formation, up-regulation
of pro-angiogenic proteins
Liu et al., 2014a
DRGN1 Granulation tissue formation,
re-epithelialization, keratinocyte
migration and proliferation via EGFR
and STAT3
Chung et al., 2017
Epi-1 Keratinocyte migration and
proliferation
Formation of collagen Huang et al., 2017
Esculentin-1a(1-21)NH2 Keratinocyte migration via EGFR and
STAT3
Di Grazia et al.,
2015b
LL-37 Keratinocyte migration via
ADAM-mediated EGFR
transactivation, HUVEC proliferation

















SHAP1 Keratinocyte migration via EGFR
transactivation and STAT3,
re-epithelialization
Kim et al., 2014






SR-0379 Granulation tissue formation, HUVEC







Tiger17 TGF-β ↑ in macrohages via JNK;





α-SMA ↑ Tang et al., 2014
Tylotoin TGF-β ↑ and IL-6 ↑ in macrophages




HUVEC proliferation and tube
formation, re-epithelialization,
granulation tissue formation
α-SMA ↑ Mu et al., 2014
WRL3 Re-epithelialization, VEGF production
→ formation of new blood vessels
Ma et al., 2017
bacteria counts in the wound with rapid killing and did
not induce resistance after 15 passages of S. aureus while
showing low hemolytic activity and high serum stability (Li
Z. et al., 2016). A distinct mechanism was found for peptides
derived from tetraspanin CD9 which blocked the adherence
of S. aureus to keratinocytes, thus inhibiting or reducing
invasion of the skin with this pathogen (Ventress et al.,
2016).
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FIGURE 4 | Proposed molecular mechanism of AMP-induced keratinocyte migration and/or proliferation via P2X7R and EGFR. AMPs induce P2X7R activation
indirectly or by acting as allosteric modulators, thus increasing sensitivity of the extracellular ligand adenosine-triphosphate (ATP). P2X7R activation leads to EGFR
transactivation via metalloprotease-mediated shedding of EGFR ligands which after cleavage from their membrane-anchored form trigger EGFR signaling. Activation
of distinct signaling pathways finally leads to migration and/or proliferation of keratinocytes.
Certain natural AMPs show strong antimicrobial activity
in vitro which is antagonized under physiological conditions
such as high salt concentrations or the presence of polyanionic
polymers like glucoseaminoglycans or mucin (Fjell et al., 2011).
Despite, they are still able to kill bacteria in vivo suggesting an
additional mechanism besides the direct antimicrobial effect. The
lactoferrin-derived AMP HLR1r decreased bacteria survival in
an ex vivo skin model infected with S. aureus although showing
a reduced in vitro efficacy in a wound-like environment (Björn
et al., 2016). Furthermore, some peptides protect against bacterial
infections in vivo without possessing direct antimicrobial activity
(Scott et al., 2007; Nijnik et al., 2010). The immunomodulatory
properties displayed by these peptides resulted in their depiction
as HDPs.
S. aureus skin infections are often associated with excessive
inflammation increasing the clinical severity of the infection
which is more central for the clinical severity of the skin infection
than the bacterial burden (Montgomery et al., 2013). Therefore,
anti-inflammatory properties of AMPs might be beneficial
particularly for the healing of chronic and non-healing wounds
such as diabetic leg ulcers. FI-PRPRPL-5 enhanced wound
closure compared to the antibiotic mupirocin in a mouse model
of MRSA skin infection and also reduced the mean bacterial
count, albeit with a less pronounced effect than the antibiotic
(Thangamani et al., 2015). In contrast, the peptide was capable
of reducing the levels of the pro-inflammatory cytokines TNF,
IL-1β, and IL-6, whilemupirocin only reduced IL-6 levels. Ca-Tx-
II inhibited NF-κB activation and secretion of pro-inflammatory
cytokines in the wound tissue of S. aureus-infected wounds, while
cytokines and chemokines such as MCP-1, that play a key role
for wound healing, were increased (Samy et al., 2014). Topical
application of the 12-mer peptide WR12 or the 8-mer peptide D-
IK8 strongly reduced bacterial counts in amouse model ofMRSA
skin infection comparable to the topical application of fusidic
acid or the oral application of linezolid (Mohamed et al., 2016).
Furthermore, the peptides decreased TNF and IL-6 secretion,
thus exhibiting an anti-inflammatory effect additionally to the
antimicrobial activity. IDR1018 accelerated wound healing in S.
aureus-infected porcine wounds and non-diabetic, but not in
diabetic mouse wounds by increasing re-epithelialization and
showed a stronger wound closure effect than LL-37 and HB-107
without displaying an antibacterial effect (Steinstraesser et al.,
2012). The authors postulated that the lack of effect in diabetic
wounds might result from suppression of the wound healing
promoting mechanism of the peptide in diabetic wounds due to
a compromised immune system.
The innate defense-regulator peptide (IDR-1) modified
signaling pathways downstream of TLRs and upregulated
chemokines that recruit monocytes and macrophages to the
site of infection, but downregulated pro-inflammatory cytokines
(Scott et al., 2007). The cathelicidin HDP fowl-1 (6-26)
protected mice from MRSA infection by enhancing the host
response via increased chemotaxis and activation of macrophages
and neutrophils (Bommineni et al., 2014). These peptides
show the advantage of selectively enhancing host immune
responses supporting the clearance of infection while on the
contrary preventing overactivation of the immune system
(Scott et al., 2007). Epi-1 recruited neutrophils to the wound
site and decreased MRSA-induced inflammation and sepsis
in heat wound-injured pigs, reflected in reduced IL-6 and
C-reactive protein serum levels (Huang et al., 2017). For
some immunomodulatory activities cell penetration of AMPs is
required and can therefore particularly be provided by peptides
that translocate not only into bacterial, but also into host cells
(Mansour et al., 2015).
Activation or regulation of the immune system by AMPs
is mainly determined by the cell type, the presence of other
pro-inflammatory stimuli and the kinetics of the inflammatory
response (Dutta and Das, 2015; Hemshekhar et al., 2016;
Pinheiro da Silva and Machado, 2017). The dual ability of
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AMPs to mediate both pro- and anti-inflammatory responses
likely takes place consecutively after an infection starting with
the pro-inflammatory response which is activating the host
immune response and thus facilitates the resolution of infection
followed by the anti-inflammatory effect to avoid excessive
inflammation. Regulation of inflammatory responses can also
be determined by the local milieu, as exemplified by IDR-1018
which could increase MCP-1 production in macrophages in
the absence of pro-inflammatory stimuli, while LPS-mediated
cytokine production was reduced by the peptide (Choe et al.,
2015). However, the most important role of AMPs seems
to be selective control of pathogen-induced inflammation
(Hemshekhar et al., 2016). Additionally, HDPs might be pro-
inflammatory at high concentrations, while anti-inflammatory at
low concentrations. hBD3 was highly expressed directly after an
infection exerting a pro-inflammatory response, while thereafter
the concentration decreased switching to an anti-inflammatory
response to resolve inflammation (Semple et al., 2011). Several
additional immunomodulatory mechanisms were found for
AMPs where interaction with receptors is involved, including
influence on dendritic cell maturation (Davidson et al., 2004;
Kang et al., 2005) via G-protein coupled receptors and activation
of the inflammasome and thus IL-1β secretion via the P2X7R
(Ferrari et al., 2004; Tomasinsig et al., 2008), while melittin was
capable of triggering IL-1β and IL-18 secretion in keratinocytes
via the AIM2 inflammasome (Dombrowski et al., 2012). IL-1β
secretion on the other side is involved in different stages of
the wound healing process. LL-37 and IL-1β acted in synergy
to promote angiogenesis (Salzer et al., 2014) and IL-1β could
promote cell migration via EGFR (Sanchez-Guerrero et al., 2012).
IDR-1018, cathelicidin-WA, and LL-37 influenced macrophage
differentiation (van der Does et al., 2010; Chen et al., 2018). IDR-
1018 provoked macrophage differentiation to an intermediate
M1–M2 state with upregulation of M2 markers such as anti-
inflammatory cytokines, but on the other side the opportunity
to switch back to pro-inflammatory M1 macrophages and thus
being able to respond adequately to infection (Mansour et al.,
2015). As M2 macrophages are essentially involved in early and
middle stages of wound repair, regulation of their differentiation
by AMPs might contribute to improved wound healing (Ferrante
and Leibovich, 2012).
Immunomodulatory effects of AMPs were also demonstrated
in keratinocytes. Reduction of IL-8 and cyclooxygenase
(COX)-2 gene expression in LPS-treated HaCaT keratinocytes
was observed with a cryptic cationic AMP from human
apolipoprotein E, probably due to direct binding to LPS (Pane
et al., 2016). Similarly, the synthetic anti-endotoxin peptides
Pep19-2.5 and Pep19-4LF which bind to and neutralize bacterial
pathogenicity factors were able to reduce cytokine secretion
in lipopeptide-stimulated keratinocytes (Pfalzgraff et al., 2016)
and non-canonical inflammasome activation induced by
cytoplasmic LPS (Pfalzgraff et al., 2017). Since keratinocytes
are an important source of pro-inflammatory cytokines in skin
inflammation and infection, the anti-inflammatory activity of
AMPs in these cells might essentially contribute to the protection
against complicated SSTIs. In addition, LL-37 protected
keratinocytes from apoptosis mediated via a COX-2-dependent
mechanism (Chamorro et al., 2009) and prolonged the life span
of neutrophils, by suppressing apoptosis via formyl peptide
receptor-like 1 and P2X7R (Nagaoka et al., 2006).
C. (formerly P.) acnes which is the second major Gram-
positive pathogen in SSTIs (Ozolins et al., 2005) and shows
increasing resistance to standard antibiotic therapies, is capable
of triggering TLR2-mediated inflammation in acne lesions (Kim
et al., 2002; Su et al., 2017). Current standard treatments are
accompanied by severe side effects and low efficiency in many
acne patients (Ryu et al., 2015). Thus, C. acnes represents an
excellent target for the treatment with antimicrobial peptides due
to their dual-immunomodulatory and antimicrobial activity and
low resistance rate (Harder et al., 2013; Lim et al., 2015). AMPs
were found to inhibit growth of C. acnes and release of pro-
inflammatory cytokines in peripheral blood mononuclear cells
while increasing anti-inflammatory cytokines (Popovic et al.,
2012). Granulysin-derived peptides were able to reduce the
clinical grade of acne when used in 30 patients as topical
formulation for 12 weeks (Lim et al., 2015). Additionally, they
showed bactericidal and anti-inflammatory activity in vitro
against C. acnes (McInturff et al., 2005). The synthetic cecropin
A–magainin 2 hybrid analog P5 was able to bind to lipoteichoic
acid, thereby reducing C. acnes-induced TLR2 up-regulation and
NF-κB nuclear translocation in keratinocytes, and to inhibit
growth of C. acnes stronger than benzoyl peroxide. In vivo, an
anti-inflammatory and antibacterial effect against C. acnes could
be demonstrated after intradermal injection of P5 following C.
acnes inoculation into mice ears (Ryu et al., 2015). Also melittin
reduced C. acnes-induced inflammatory responses in vitro and
in vivo by down-regulating pro-inflammatory cytokines and
TLR2, thereby mediating its anti-inflammatory effect via NF-κB
signaling (Lee et al., 2014).
As described above, the diverse immunomodulatory activities
exhibited by HDPs underline the potential of AMPs for the
therapeutical use in SSTIs and wounds. Specifically, AMPs
possess various features beneficial for wound healing, including
their direct antimicrobial effect which prevents infection that
would otherwise delay wound healing.Wound recovery is further
supported by immunomodulatory activities such as chemotactic
activity toward macrophages and neutrophils, neutralization
of bacterial pathogenicity factors and modulation of cytokine
release which reduce detrimental pro-inflammatory responses.
For the treatment of non-infected wounds, promotion of
cell migration and proliferation, induction of angiogenesis,
stimulation of collagen synthesis and wound contraction are
especially favorable. However, it should be noted that many in
vivo wound healing studies with AMPs were conducted in mice
where wound healing mainly occurs via contraction and not re-
epithelialization and granulation tissue formation (Wong et al.,
2011). Thus, alternative preclinical models should be considered
for in vivo wound healing experiments, as already realized for
a number of AMPs that could show high activity in pig wound
healing models (Ansell et al., 2012).
Treatment of Biofilms
A major issue in the treatment of SSTIs and wounds, but also in
implants, are bacterial biofilms, a structured, surface-associated
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assemblage of microorganisms enclosed in an extracellular
biopolymeric matrix. Compared to planktonic (free swimming)
cells, bacteria growing in biofilms are 10- to 1,000-fold more
resistant to conventional antibiotics, mostly due to limited
penetration of antibiotics, and are estimated to account for
at least 65% of all human infections and often result in
chronification of infections and wounds. Biofilms are particularly
difficult to eradicate due to their resistance to exogenous stresses
such as therapy with conventional antibiotics and host defense
mechanisms like opsonisation and phagocytosis (Luca et al.,
2013; de la Fuente-Núñez et al., 2015). The biofilm constitutes a
permeability barrier for antibiotics and the bacterial population
within the biofilm is very heterogenic with a mixture of
metabolically active and inactive cells (Stewart and Costerton,
2001; Batoni et al., 2011). In vitro and in vivo biofilm formation
was demonstrated for pathogens involved in skin diseases such
as S. aureus and Streptococcus pyogenes (Percival et al., 2012),
but also P. aeruginosa, which when colonizing wounds, existed as
biofilms rather than single cells (Kirketerp-Moller et al., 2008). S.
aureus biofilms were shown to be more difficult to eradicate than
their planktonic counterparts and may play an important role in
acute and chronic cutaneous wound infections that are refractory
to therapy (Davis et al., 2008). S. aureus and S. epidermidis
biofilms formed in a mouse wound model caused disruption of
normal re-epithelialization (Schierle et al., 2009). Additionally,
the occurrence of biofilms is much greater in chronic compared
to acute wounds (James et al., 2008). Thus, therapies that try
to eradicate biofilms might improve recovery and healing of
infected wounds.
IDR-1018 possesses a broad-spectrum anti-biofilm activity
due to inhibiting a common stress response in bacteria (de
la Fuente-Nunez et al., 2014). It promoted degradation of
the widespread signaling nucleotide guanosine penta- and
tetra-phosphate (p)ppGpp, an important signal in biofilm
development and stress responses, and synergistically interacted
with distinct antibiotics to prevent and eradicate bacterial
biofilms (Reffuveille et al., 2014). The broad-spectrum anti-
biofilm activity seems to originate from its prevention of
(p)ppGpp-induced signaling effects. Other AMPs such as LL-
37, which are able to prevent biofilm formation, inhibited initial
bacteria attachment and quorum sensing systems and stimulated
twitching motility and thus did not show a broad-spectrum
anti-biofilm activity (Overhage et al., 2008). While 1,037, a
synthetic, 9-amino-acid peptide, with very weak antimicrobial
activity, inhibited biofilm formation of Gram-negative and
Gram-positive bacteria also by stimulating twitching motility, it
additionally reduced flagella-dependent swimming motility and
bacterial swarming, and downregulated genes involved in biofilm
formation including the quorum-sensing-regulated gene rhlB (de
la Fuente-Nunez et al., 2012). A synthetic helical cathelicidin
derived from NA-CATH, identified in a Chinese cobra, inhibited
S. aureus biofilm formation also in the presence of salt with
a stronger activity than NA-CATH and LL-37 and D-LL-37,
thereby not affecting bacterial attachment, while LL-37 and D-
LL37 reduced attachment of S. aureus. Interestingly, the anti-
biofilm activity of all these peptides was salt-independent, while
they lost their antimicrobial activity against planktonic bacteria
(Dean et al., 2011a). In contrast, synthetic peptide variations of
NA-CATH did not inhibit biofilm formation of P. aeruginosa
(Dean et al., 2011b). The unnatural, proline rich AMP FI-
PRPRPL-5 was able to reduce biofilm mass from preformed
biofilms generated by S. aureus strains stronger than mupirocin
and vancomycin (Thangamani et al., 2015). Also lactoferrin
increased twitching motility of P. aeruginosa by decreasing free
iron levels due to chelating iron and thus is able to block biofilm
development (Singh et al., 2002). In combination with xylitol,
lactoferrin could inhibit growth of established biofilms of a
clinical wound isolate from P. aeruginosa and a lactoferrin/xylitol
hydrogel in combination with silver wound dressings showed a
stronger biofilm viability reduction than a commercially available
wound hydrogel in P. aeruginosa and MRSA (Ammons et al.,
2011).
Acylation of AMPs can have an influence on the bactericidal
effect against planktonic and biofilm bacteria. In synthetic
peptides, based on LF-11, an 11-mer peptide derived from human
lactoferricin, peptide acylation increased the antimicrobial
activity against planktonic bacteria (Sanchez-Gomez et al., 2015).
Hydrophobicity, however, reduced anti-biofilm activity, probably
due to interaction with exopolysaccharide components of the
biofilm resulting in aggregation and thus reduced penetration,
as suggested by the authors. In contrast, for cyclic lipopeptides
derived from fusaricidin/LI-F class of AMPs, an increase of
overall hydrophobicity and net positive charge improved activity
against biofilms due to an improved biofilm penetration (Bionda
et al., 2016). These peptides, like peptides targeting (p)ppGpp,
also showed a broad-spectrum anti-biofilm activity.
Another mechanism of action for anti-biofilm activity is
displayed by the amphibian skin peptide esculentin (1–21) which
disrupted biofilms by bacterial membrane perturbation of P.
aeruginosa with increased leakage of the cytosolic enzyme β-
galactosidase (Luca et al., 2013). The same mode of action
was exhibited by the peptide against free-living forms of P.
aeruginosa. Since the effect occurred within 15min intracellular
processes can be excluded. Bacteriocins caused formation of
stable pores on biofilm cells which resulted in ATP eﬄux
and consequently cell death. For the two bacteriocins nisin
A and lacticin Q penetration of the biofilm matrix could be
demonstrated reaching the deepest part of the biofilm (Okuda
et al., 2013). Also the small lytic peptide PTP-7 was able to
diffuse into deep layers of S. aureus biofilms and kill bacteria
inside the biofilm by causing cell lysis (Kharidia and Liang,
2011). RRIKA and RR were able to disperse mature S. aureus
and S. epidermidis biofilms with a stronger biofilm reduction
than the antibiotics vancomycin and linezolid (Mohamed et al.,
2014). Further AMPs with specific anti-biofilm activity are the
tryptophane-rich antibacterial peptides KT2 and RT2 preventing
E. coli biofilm formation and killing bacteria in mature E.
coli biofilms by translocating across the bacterial membrane
after binding to bacterial surface LPS and binding to DNA
after entry into the bacterial cells (Anunthawan et al., 2015).
Stereospecificity seems to play an important role for anti-biofilm
activity as IK8L, a short synthetic peptide with all L-amino
acids (AA) was more active against MDR P. aeruginosa biofilms
than the same peptide with 4 D-AA or an all D-AA peptide
Frontiers in Pharmacology | www.frontiersin.org 13 March 2018 | Volume 9 | Article 281
Pfalzgraff et al. AMPs for Treatment of Skin Infections and Wounds
(Zhong et al., 2017). Furthermore, it was superior to the antibiotic
ceftazidime with more rapid bactericidal activity in vitro with
the advantage of negligible resistance and superior to imipinem
as topical application in vivo in an infected mouse burn wound
model by increasing survival and reducing bacterial counts. The
synthetic and anti-biofilm peptide SAAP-148 was applied as a
single 4-h treatment in hypromellose ointment and completely
eradicated acute and established, biofilm-associated infections
with MRSA and MDR A. baumannii from wounded ex vivo
human skin and mouse skin in vivo (de Breij et al., 2018).
Cyclic lipopeptides showed strong activity against staphylococcal
biofilms in a porcine wound model (Bionda et al., 2014) and
DJK-5 and DJK-6 appear to be promising candidates to treat
biofilms in vivo since they protected the invertebrate organisms
Caenorhabditis elegans and Galleria mellonella from otherwise
lethal P. aeruginosa biofilm infections (de la Fuente-Núñez et al.,
2015). DRGN-1 was able to promote wound healing in mixed
biofilm-infected wounds by inducing the clearance of S. aureus
and P. aeruginosa biofilms combined with increased keratinocyte
migration (Chung et al., 2017). Importantly, the AMPs tested
for anti-biofilm activity in vivo showed negligible toxicity (de
la Fuente-Núñez et al., 2015; Zhong et al., 2017; de Breij et al.,
2018).
It is evident from the above studies that AMPs as anti-
biofilm agents possess advantageous features such as their
broad-spectrum, rapid activity, low susceptibility to resistance
development and a bactericidal effect independent of the
bacterial growing state, whereas conventional antibiotics kill
actively dividing cells.
STRATEGIES TO IMPROVE TOPICAL
BIOAVAILABILITY OF AMPs
In general, topical therapy is preferred over systemic drug
administration in skin diseases to avoid systemic adverse
effects. However, topical application requires sufficient tissue
penetration (Stein and Wells, 2010). The skin, especially the
stratum corneum, represents an effective barrier for topical
treatment due to highly organized stratum corneum lipids, thus
impeding the penetration of peptides into the skin. Additionally,
rapid degradation e.g., by aminopeptidases and esterases might
limit the topical use of AMPs, particularly for large molecules
such as melittin, a 26-amino acid peptide, but also for hydrophilic
and very lipophilic molecules. However, skin penetration of
AMPs like melittin might be facilitated by their membrane-
disrupting mode of action and their cytotoxic effect. For some
AMPs penetration in deeper layers of the skin was demonstrated
revealing slow access to the viable skin after 24 h (Do et al.,
2014). Another major issue for the clinical use of AMPs is their
low stability in vivo, e.g., toward bacterial proteases, but also
to endogenous proteases such as trypsin-like proteases that are
abundant in the body (e.g., in wound exsudate) and selective for
basic residues. The majority of naturally occurring AMPs have
unfavorable pharmacokinetic properties such as a very short half-
life of only 1–2 h, mainly due to degradation by proteases (Di
Grazia et al., 2015a). Thus, if intended for clinical use, peptides
should be examined for skin penetration and effects of skin
enzymes on peptide activity.
Several strategies exist to improve the bioavailability of
AMPs for topical application (Figure 5). To enhance penetration
different approaches can be used such as administration together
with penetration enhancers, encapsulation into hydrophobic
carriers or chemical modifications of the peptides to increase
lipophilicity (Namjoshi and Benson, 2010). A combination of
an enzyme which inhibits biofilm formation and disperses pre-
formed biofilms with an anti-biofilm peptide in a gel formulation
showed synergistic effects against chronic wound infections
(Gawande et al., 2014). Since drug permeation through the
stratum corneum is widely dependent on molecular size and
lipophilicity, smaller AMPs display the advantage of improved
penetration. A molecular weight lower than 500 Da (Bos
and Meinardi, 2000) and moderate lipophilicity and aqueous
solubility are ideal characteristics for successful transdermal
delivery. Furthermore, antimicrobial peptides used for topical
application should not be absorbed from the wound or infection
site into the systemic circulation and not provoke allergic
sensitization which could be demonstrated for pexiganan which
already passed through clinical trials for the treatment of mildly
infected, diabetic foot ulcers, but was not approved by the
FDA despite being clinical comparable to the oral antibiotic
ofloxacin (Lipsky et al., 2008). Skin penetration of AMPs might
be improved by cyclization which improves their chemical and
enzymatic stability, receptor selectivity, and pharmacodynamic
properties (Namjoshi and Benson, 2010). An alternative
therapeutic option could be the induction of endogenous AMPs
as demonstrated for aroylated phenylenediamines which could
induce LL-37 up to 20- to 30-fold in vitro (Ottosson et al., 2016).
Different approaches were made to improve the stability
of AMPs such as introduction of D-AA (Gao et al., 2016).
For cationic α-helical peptides a minimum ratio of D-AA
of 33% was shown to be required for complete resistance
to enzymatic degradation (Lee et al., 2005; Wang et al.,
2010). D-AA further prohibit aggregation of AMPs and reduce
toxicity due to destabilized helical structures (Li H. et al.,
2016). Likewise, modifications of the terminal regions such as
FIGURE 5 | Factors most likely determining the extent of topical bioavailability
of AMPs.
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acetylation, amidation and hydrophobic tagging and the use of
peptidomimetics reduce susceptibility to proteases (Ebbensgaard
et al., 2015; Ageitos et al., 2017). Another possibility is
substitution with the amino acid tryptophan which could reduce
proteolytic degradation of the LL-37-derived peptide EFK17 and
improved its antimicrobial potency (Stromstedt et al., 2009).
WR12 which is exclusively composed of Trp and Arg residues
showed an improved antimicrobial salt stability compared to
pexiganan (Mohamed et al., 2016). Likewise pegylation can
increase resistance to bacterial proteases (Falciani et al., 2014).
Another promising approach seems to be the coating of
biomaterials like biomedical devices and implants with AMPs
which showed encouraging effects in vitro (Kazemzadeh-Narbat
et al., 2010; Deslouches et al., 2015; Kasetty et al., 2015; Yazici
et al., 2016) and in vivo (Choe et al., 2015; Chen et al., 2016),
hence reducing bacterial colonization and allowing controlled
release of the peptides with high concentrations for prolonged
periods. For this purpose the peptides can be incorporated in
distinct matrices such as a polymer-lipid encapsulation matrix
(de Breij et al., 2016).
Salt resistance and serum stability can be improved by
insertion of the non-natural amino acid β-naphtlylalanine or
replacement of tryptophans and histidines in Trp- and His-
rich AMPs with this bulky amino acid, which on the other side
increases hemolytic activity (Chu et al., 2013). Also tryptophane
end tagging can improve salt stability with the advantage of lower
hemolytic activity compared to β-naphtlylalanine.
To improve the bioavailability of AMPs several drug delivery
systems such as hydrogels (Xie et al., 2015), poly(lactic-co-
glycolic acid) (PLGA) nanoparticles, or lipid-based peptide
encapsulation systems (MeIkle et al., 2017) with incorporated
AMPs were investigated with sustained delivery of the peptides
and controlled release. Furthermore, delivery systems can
improve solubility and provide targeted delivery. Esculentin-
1a(1-21)NH2 coated on gold-nanoparticles (AuNPs) showed
increased activity against P. aeruginosa and resistance to
proteolytic digestion compared to the free peptide (Casciaro
et al., 2017). The advantage for topical therapy using AuNPs
is their ability to penetrate all layers of human skin to a
greater extent than other metal nanoparticles such as silver
NPs. LL-37-conjugated gold nanoparticles showed higher in vivo
wound healing activity compared to LL-37 alone and prolonged
phosphorylation of EGFR and ERK1/2 in vitro, thus improving
cell migration (Comune et al., 2017). Encapsulation of solid
lipid nanoparticles (SLNs) with LL-37 in the combination with
the elastase inhibitor Serpin A1 provided a biphasic release
profile with strong release at the beginning and sustained
release afterwards over the entire study period of 15 days while
permeation of LL-37 alone discontinued after 2 days (Fumakia
and Ho, 2016). This formulation was protecting the peptide
from degradation and could permeate across the skin, while
accelerating wound healing in vitro and showing synergistic
effects against S. aureus and E. coli compared to the single
drug. Coating of various surfaces with battacin lipopeptides
prevented colonization by P. aeruginosa and E. coli biofilms
and might thus be used for preventing colonization of medical
implants (De Zoysa and Sarojini, 2017). The importance of the
formulation was further demonstrated for the AMP P60.4Ac
which was investigated in two different cream formulations, PBS
or a hypromellose gel (Haisma et al., 2016). In the gel formulation
P60.4Ac was most effective against S. aureus, including MRSA
and mupirocin-resistant MRSA, while its antimicrobial activity
was reduced in the cream formulations and in PBS. While the
peptide seemed to be released from the gel in adequate amounts
within a longer time interval, release from cream formulations
appeared insufficient. A3-APO and its monomeric metabolite
were applied topical or i.m. revealing the same effectiveness in
mouse models of intradermal infection of a burn wound with
MRSA or intradermal infection with C. acnes (Ostorhazi et al.,
2013). Moreover, when APO was incorporated into polyvinyl
alcohol nanofiber which was polymerized into a solid patch
dressing, it enhanced wound healing and reduced bacterial load
superior to the antibiotic colistin in Acinetobacter baumanii-
infected skin wounds in mice. The antibacterial activity in vivo
of the peptide-loaded patch dressing was exceeding the effect of
i.m. administration of the peptide without the dressing, probably
due to a controlled release from the wound dressing (Sebe
et al., 2016). For medical application wound dressings seem to
be a promising option as demonstrated for cotton gauze with
Cys-LC-LL-37 or magainin 1 which blocked bacterial growth
while showing very low cytotoxicity (Gomes et al., 2015). AMP
encapsulation in a thermosensitive hydrogel or incorporation of
peptides conjugated to dextrin into hydrogels has been described
(Li et al., 2015; Silva et al., 2015). While improving bioavailability,
the local delivery system can also serve as drug depot with
sustained release of the peptides and leading to a higher local drug
concentration. These delivery systems should be biocompatible,
non-immunogenic, and biodegradable (Chereddy et al., 2014).
PERSPECTIVES FOR FUTURE THERAPY
Antibiotics have the major disadvantage to cause release of
PAMPs from pathogens resulting in damaging inflammation
and sepsis. This especially applies to antibiotics targeting the
bacterial cell wall (Brandenburg et al., 2016). Hence, combination
therapy of antibiotics together with antimicrobial peptides seems
to be a promising approach and might prevent the development
of bacterial resistance and reduce the drug dose required.
Especially dose reduction is an important factor since this can
reduce side effects which in turn play a critical role for clinical
development.
AMPs can further act as antiresistance compounds for
conventional antibiotics, e.g., via facilitating the access of
antibiotics into bacterial cells by increasing the permeability
of the cytoplasmic membrane (Mataraci and Dosler, 2012).
Azithromycin acted in synergy with LL-37 and colistin which
increased the permeability of the outer membrane of Gram-
negative bacteria and thus facilitated the entry of azithromycin
(Lin et al., 2015). The synthetic AMPs RRIKA and RR
showed synergistic activity with lysostaphin against MSSA,
MRSA, and VRSA isolates (Mohamed et al., 2014). The
authors speculated that the synergistic effect might be due to
lysostaphin-induced cleavage of peptidoglycan which is located
in the cell wall allowing a better access of the peptides to
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the cell membrane. Esculentin-1b(1-18)NH2 in subinhibitory
concentrations exhibited synergism with erythromycin and
other antibiotics since it was able to increase the membrane
permeability of E. coli, thus enhancing the access of the
antibiotic to its intracellular target (Marcellini et al., 2009).
Additionally, synergism could be shown for the combination of
two antimicrobial peptides (Capparelli et al., 2009; Rahnamaeian
et al., 2015; Zhao et al., 2015; Field et al., 2016; Mohamed
et al., 2016) whereas combination of three AMPs displayed
an even stronger synergism (Yu et al., 2016). The fact that
AMPs can synergize with other AMPs and not only with
conventional antibiotics might be used to increase therapeutic
efficacy. IDR-1018 and DJK-5 and DJK-6 were acting in synergy
with conventional antibiotics to prevent biofilm formation and
treat pre-existing biofilms which allowed the use of lower
concentrations of the antibiotics (Reffuveille et al., 2014; de la
Fuente-Núñez et al., 2015). The proposed mechanism for the
synergism was explained by an increased bacterial susceptibility
to antibiotics due to the capability of the peptides to target
(p)ppGpp and to downregulate genes involved in the mechanism
of action of antibiotics and biofilm formation. Furthermore,
it could be demonstrated that AMPs are able to extend the
spectrum of antibiotics. For the conjugation of the mouse peptide
CRAMP and the antibiotic vancomycin, normally used for the
treatment of infections with Gram-positive bacteria, activity
against both Gram-positive and Gram-negative bacteria was
shown, presumably due to translocation of vancomycin into
the periplasm of Gram-negative bacteria enabled by the AMP
(Pletzer et al., 2016). Additionally, AMPs are able to suppress
resistance of bacteria to conventional antibiotics (Mohamed
et al., 2016). Incubation with subinhibitory concentrations of the
12-mer peptide WR12 with VRSA strains re-sensitized them to
the effect of vancomycin, teicoplanin, and oxacillin. The synthetic
α-helical peptide PL-5 showed synergism with levofloxacin in a
S. aureus mouse infection model in vivo, probably due to a dual
mode of action with the peptide targeting the bacterial membrane
and the antibiotic with cytoplasmic targets (Feng et al., 2015).
Thus, it would be expected that combination therapies will
have several major advantages including broad spectrum of
coverage, the ability to reduce concentrations of single drugs and
thus their side effects and to delay drug resistance evolution.
CONCLUSION AND PERSPECTIVE
Enormous progress has been made in peptide development
and in unveiling the various characteristics of AMPs. Favorable
features for the treatment of skin infections and wounds are
the efficacy against biofilms, the capability of promoting wound
healing and the ability to modulate immunity by increasing
protective immunity while on the other side dampening
overwhelming inflammatory responses accompanied in part by
direct antimicrobial effects.
The dual bioactivity displayed by AMPs, namely their
propensity to control both infection and inflammation, might
be beneficial particularly for the treatment of chronic wounds
and complicated SSTIs associated with strong inflammatory
responses. While supporting infection-resolving immunity
and modulating innate immunity, they dampen potentially
harmful pro-inflammatory responses. Nevertheless, their diverse
functions in immunity elicited by binding to distinct receptors
or influencing different intracellular signaling pathways still have
to be elucidated to avoid occurrence of side effects that could
emerge when using these highly potent molecules in therapy.
Tight regulation of AMPs is required since high or persistent
amounts might cause chronic inflammation as demonstrated for
psoriasis and rosacea.
The knowledge regarding direct interaction between AMPs
and endogenous receptor proteins is still very limited. The
natural AMP LL-37 is highlighting the complexity of the
interaction between AMPs and the host since it is interacting
with at least 16 proteins and receptors, thereby influencing more
than 1,000 secondary effector proteins (Hancock et al., 2016).
However, more than two decades of work were required to
decipher the complex mechanisms reflecting its interaction with
the host since it was first identified in 1995 (Vandamme et al.,
2012). It would be interesting to decipher the distinct activities
of AMPs that support wound healing and to identify relevant
peptide structures, to develop peptides that ideally possess several
features that are favorable for wound healing. However, peptides
that are activating growth factor receptors should be screened
for their potential to induce tumorigenesis (Weber et al., 2009).
Additionally, in vivo testing of AMPs is unconditionally required
as isolated cell systems cannot reflect the complexity of the innate
immune response (Easton et al., 2009).
Despite the great efforts that were made by several research
groups to design new peptides with improved properties, only
few AMPs have been introduced to the market or are in clinical
trials (Greber and Dawgul, 2017; Kang et al., 2017). Nevertheless,
most of the studies conducted concentrate on topical therapy for
indications such as acne vulgaris, rosacea, or chronic wounds
revealing the promising therapeutic applicability of AMPs for
these medical indications.
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